Drupal.behaviors.print = function(context) {window.print();window.close();}>
454 Revenues Pick Up in Q3, But Roche's Overall Genomic Sales Decline 12 Percent Year to Date
October 18, 2011
454 Revenues Pick Up in Q3, But Roche's Overall Genomic Sales Decline 12 Percent Year to Date
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Roche Achieves Sequencing on Semiconductor Platform; Automating ePCR with Japanese Partner
January 22, 2013 / In Sequence
Study Finds Roche's NGS-Based HIV Assay Comparable to TruGene; Company Expects 2014 CE-IVD Approval
January 30, 2013 / Clinical Sequencing News
IRON-II Study Uses 454 Sequencing to Investigate New Markers for Hematological Malignancies
September 12, 2012 / Clinical Sequencing News
In Applied Science Restructuring, Roche Exits Microarrays, Bundles 'Sequencing Solutions,' R&D
June 12, 2012 / In Sequence
Roche 454 GS Junior Sales Increase in 2011, While GS FLX Reagent Revenue Drops
February 7, 2012 / In Sequence